Current Cardiology Reports

, 13:537 | Cite as

Apo A-I Modulating Therapies

Lipid Abnormalities and Cardiovascular Prevention (Michael H. Davidson, Section Editor)


The substantial residual risk of cardiovascular events despite the implementation of effective lowering of low-density lipoprotein cholesterol highlights the need to develop additional cardioprotective therapies. Evidence from population and animal studies suggests that high-density lipoproteins (HDLs), the protective lipid particles, may represent a target for therapeutic modification. As a result intensive efforts are in progress to develop new agents that promote HDL activity. Among these different approaches, a range of strategies that target apolipoprotein A-I, the major protein carried on HDL, are being evaluated.


Apolipoprotein A-I High-density lipoproteins Risk factors Atherosclerosis Lipids Coronary artery disease 



Conflicts of interest: S.J. Nicholls: has been a consultant for Roche, Merck, Sanofi-Aventis, Omthera, AstraZeneca, and Pfizer; and has received grant support from AstraZeneca, Eli Lilly, Resverlogix, Anthera, Roche, and Novartis.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    •• Vaisar T, Pennathur S, Green PS, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest. 2007;117:746–56. This paper characterizes a substantial number of proteins carried on HDL particles. PubMedCrossRefGoogle Scholar
  2. 2.
    Barr DP, Russ EM, Eder HA. Protein-lipid relationships in human plasma. II. In atherosclerosis and related conditions. Am J Med. 1951;11:480–93.PubMedCrossRefGoogle Scholar
  3. 3.
    Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62:707–14.PubMedCrossRefGoogle Scholar
  4. 4.
    • Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301–10. This paper highlights the importance of a low HDL cholesterol in patients with very low levels of LDL cholesterol.PubMedCrossRefGoogle Scholar
  5. 5.
    Badimon JJ, Badimon L, Galvez A, Dische R, Fuster V. High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits. Lab Invest. 1989;60:455–61.PubMedGoogle Scholar
  6. 6.
    Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest. 1990;85:1234–41.PubMedCrossRefGoogle Scholar
  7. 7.
    Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Nat Acad Sci USA. 1994;91:9607–11.PubMedCrossRefGoogle Scholar
  8. 8.
    Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 1991;353:265–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Ameli S, Hultgardh-Nilsson A, Cercek B, et al. Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. Circulation. 1994;90:1935–41.PubMedGoogle Scholar
  10. 10.
    Nicholls SJ, Cutri B, Worthley SG, et al. Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol. 2005;25:2416–21.PubMedCrossRefGoogle Scholar
  11. 11.
    Rong JX, Li J, Reis ED, et al. Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation. 2001;104:2447–52.PubMedCrossRefGoogle Scholar
  12. 12.
    Shah PK, Yano J, Reyes O, et al. High-dose recombinant apolipoprotein A-IMilano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice. Circulation. 2001;103:3047–50.PubMedCrossRefGoogle Scholar
  13. 13.
    Brewer Jr HB. HDL metabolism and the role of HDL in the treatment of high-risk patients with cardiovascular disease. Curr Cardiol Rep. 2007;9:486–92.PubMedCrossRefGoogle Scholar
  14. 14.
    Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res. 2004;95:764–72.PubMedCrossRefGoogle Scholar
  15. 15.
    Shaul PW, Mineo C. HDL action on the vascular wall: is the answer NO? J Clin Invest. 2004;113:509–13.PubMedGoogle Scholar
  16. 16.
    Nicholls SJ, Dusting GJ, Cutri B, et al. Reconstituted high density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation. 2005;111:1543–50.PubMedCrossRefGoogle Scholar
  17. 17.
    Kraus WE, Houmard JA, Duscha BD, et al. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med. 2002;347:1483–92.PubMedCrossRefGoogle Scholar
  18. 18.
    • Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 2007;297:499–508. This paper highlights the importance of small increases in HDL cholesterol in predicting statin effects on plaque.PubMedCrossRefGoogle Scholar
  19. 19.
    Cui Y, Watson DJ, Girman CJ, et al. Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study). Am J Cardiol. 2009;104:829–34.PubMedCrossRefGoogle Scholar
  20. 20.
    Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin. 2004;20:627–37.PubMedCrossRefGoogle Scholar
  21. 21.
    Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 375:1875–84.Google Scholar
  22. 22.
    Brown BG, Zhao X-Q, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583–92.PubMedCrossRefGoogle Scholar
  23. 23.
    Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med. 2009;361:2113–22.PubMedCrossRefGoogle Scholar
  24. 24.
    Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245–55.PubMedCrossRefGoogle Scholar
  25. 25.
    Barter PJ, Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein. A novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol. 2003;23:160–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–22.PubMedCrossRefGoogle Scholar
  27. 27.
    Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356:1304–16.PubMedCrossRefGoogle Scholar
  28. 28.
    Bots ML, Visseren FL, Evans GW, et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet. 2007;370:153–60.PubMedCrossRefGoogle Scholar
  29. 29.
    Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med. 2007;356:1620–30.PubMedCrossRefGoogle Scholar
  30. 30.
    Vergeer M, Stroes ES. The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors. Am J Cardiol. 2009;104:32E–8E.PubMedCrossRefGoogle Scholar
  31. 31.
    Yvan-Charvet L, Matsuura F, Wang N, et al. Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. Arterioscler Thromb Vasc Biol. 2007;27:1132–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Nicholls SJ, Tuzcu EM, Brennan DM, Tardif JC, Nissen SE. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation. 2008;118:2506–14.PubMedCrossRefGoogle Scholar
  33. 33.
    Angelin B, Parini P, Eriksson M. Reverse cholesterol transport in man: promotion of fecal steroid excretion by infusion of reconstituted HDL. Atheroscler Suppl. 2002;3:23–30.PubMedCrossRefGoogle Scholar
  34. 34.
    Bisoendial RJ, Hovingh GK, Levels JHM, et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation. 2003;107:2944–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Spieker LE, Sudano I, Hurlimann D, et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation. 2002;105:1399–402.PubMedCrossRefGoogle Scholar
  36. 36.
    van Leuven SI, Birjmohun RS, Franssen R, et al. ApoAI-phosphatidylcholine infusion neutralizes the atherothrombotic effects of C-reactive protein in humans. J Thromb Haemost. 2009;7:347–54.PubMedCrossRefGoogle Scholar
  37. 37.
    Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290:2292–300.PubMedCrossRefGoogle Scholar
  38. 38.
    Nicholls SJ, Uno K, Kataoka Y, Nissen SE. ETC-216 for coronary artery disease. Expert Opin Biol Ther. 2011;11:387–94.PubMedCrossRefGoogle Scholar
  39. 39.
    Nicholls SJ, Tuzcu EM, Sipahi I, et al. Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano. J Am Coll Cardiol. 2006;47:992–7.PubMedCrossRefGoogle Scholar
  40. 40.
    Sirtori CR, Calabresi L, Franceschini G, et al. Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study. Circulation. 2001;103:1949–54.PubMedGoogle Scholar
  41. 41.
    Tardif JC, Gregoire J, L’Allier PL, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA. 2007;297:1675–82.PubMedCrossRefGoogle Scholar
  42. 42.
    • Waksman R, Torguson R, Kent KM, et al. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J Am Coll Cardiol. 2010;55:2727–35. This paper shows evidence that delipidated HDL promotes regression of coronary atherosclerosis.PubMedCrossRefGoogle Scholar
  43. 43.
    Bailey D, Jahagirdar R, Gordon A, et al. RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. J Am Coll Cardiol. 55:2580–9.Google Scholar
  44. 44.
    Nicholls SJ, Gordon A, Johansson J, et al. Efficacy and safety of a novel oral inducer of apolipoprotein A-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial. J Am Coll Cardiol. 2011;57:1111–9.PubMedCrossRefGoogle Scholar
  45. 45.
    Sherman CB, Peterson SJ, Frishman WH. Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis. Cardiol Rev. 18:141–7.Google Scholar
  46. 46.
    Watson CE, Weissbach N, Kjems L, et al. Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function. J Lipid Res. 2011;52:361–73.PubMedCrossRefGoogle Scholar
  47. 47.
    Bhattacharyya T, Nicholls SJ, Topol EJ, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA. 2008;299:1265–76.PubMedCrossRefGoogle Scholar
  48. 48.
    Nicholls SJ, Zheng L, Hazen SL. Formation of dysfunctional high-density lipoprotein by myeloperoxidase. Trends Cardiovasc Med. 2005;15:212–9.PubMedCrossRefGoogle Scholar
  49. 49.
    Wang Z, Nicholls SJ, Rodriguez ER, et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med. 2007.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of Cardiovascular MedicineHeart & Vascular Institute, Cleveland ClinicClevelandUSA

Personalised recommendations